Anupindi SA, Bedoya MA, Lindell RB, et al. Diagnostic Performance of Whole-Body MRI as a Tool for Cancer Screening in Children with Genetic Cancer-Predisposing Conditions. AJR Am J Roentgenol 2015;205:400–408.
Get the latest international news and world events from around the world.
Identifying Genomic Biomarkers of Rare Disease Subtypes Using Minority-Weighted Feature Selection
Introduces a novel minority-aware and robust feature selection framework, GenMWS, for high-dimensional class-imbalanced gene expression data.
Constructs class-specific core intervals and weighted own-class/other-class membership scores to capture gene-wise class structure.
Develops a weighted nonoverlap mask and class-specific support summaries to emphasize minority-class informative patterns while controlling majority-supported structure.
Top Longevity Experts Debate Each Other About Extending Human Lifespan
What if the fastest way to a longer life isn’t a miracle drug, but a wartime mentality against aging?
This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved.
Curious about quantum energy wellness? Check out Leela Quantum Tech. Check out https://leelaq.com/
On this episode of Beyond Tomorrow, four heavyweights of the longevity field take a rapid-fire statement format and turn it into a real debate. Aubrey de Grey, Alex Zhavoronkov (Insilico Medicine), George Church (Harvard Medical School), Michael Ringel (Life Biosciences) argue over whether hype helps or hurts the field, and when longevity escape velocity, the point where damage is repaired faster than it accumulates, might actually arrive. Aubrey puts it at a 50/50 chance within 12 to 15 years. Alex says 20 to 50 years and doubts drugs alone can get there. Michael pushes back on the idea of infinite lifespans entirely, while George suggests we may already be gaining years without the evidence to prove it.
From there the panel digs into the FDA’s new interest in aging, why the TAME metformin trial never opened the floodgates, and whether AI will really shrink clinical timelines. George cites a gene therapy that reached a patient in seven months, while Alex, running many programs, argues that biology still moves at the speed of traffic. The back half covers biohacking and early adopters, the gap between everyday \.
Alef flying car takes on Tesla Roadster with new flight demonstration
California-based Alef Aeronautics released a video on Thursday showing its electric flying car soaring over a Tesla Roadster, welcoming the automaker to what it calls the “flying car race.”
The company said the demonstration marked its 1,000th logged flight. It follows an earlier video showing Alef’s Model Zero Ultralight driving and flying, including a flight over a Tesla Cybertruck.
Stanford CS146S: How always-on agents work
How do always-on AI agents actually work—and what makes them capable of handling tasks even when you’re not actively prompting them?
In a lecture for Stanford’s CS146S course, Lee Robinson, formerly of Vercel and Cursor and now part of SpaceX’s AI team, explains the engineering behind Grok Bot and the emerging architecture of persistent, proactive AI agents.
The 45-minute lecture covers:
→ What changed in models to make always-on agents possible.
→ The architecture behind persistent agents.
→ Harness engineering: the systems that enable models to use tools and take action.
→ Context engineering for long-running tasks.
→ Where agent architectures are headed next.
The central insight: An AI agent is more than a model. Its ability to work autonomously over extended periods depends on the surrounding infrastructure—tool use, memory, context management, and the harness that coordinates its actions.
A useful look at the engineering required to move beyond conversational AI toward agents that can work continuously, respond to events, and manage complex tasks over time.
Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response
Purpose Bevacizumab is an effective treatment for radiation necrosis; however, dose –dependent radiographic and edema response data are lacking. Methods Multicenter, retrospective cohort study of adult patients with primary central nervous system (CNS) tumors or brain metastases who received bevacizumab for radiation necrosis between June 2021 and July 2024. Patients were grouped by bevacizumab dose (7.5 mg/kg vs. 10 mg/kg administered every three weeks). Primary outcome was edema response, assessed by a blinded neuro-oncologist. Secondary outcomes included contrast enhancing disease response, clinical response, adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis. Analyses were performed with and without adjustment for tumor type. Results 104 patients were included (7.5 mg/kg, n = 53; 10 mg/kg, n = 51). Tumor type differed significantly between cohorts (p < 0.001), with more primary CNS tumors in the 10 mg/kg group. Edema response differed between dosing groups in unadjusted analyses (p = 0.032), favoring the 7.5 mg/kg cohort; however, this association was attenuated after adjustment for tumor type. Contrast enhancing disease response did not differ between groups in either unadjusted or adjusted analyses (p = 0.43). Clinical response was higher in the 7.5 mg/kg group (65.2% vs. 37.8%, p = 0.013). Rates of adverse events, treatment discontinuation, and re-dosing were similar. Conclusions Taken together, both 7.5 mg/kg and 10 mg/kg dosing strategies achieved similar radiographic outcomes. Prospective, tumor-stratified studies incorporating edema-focused and patient-centered endpoints are needed to better define optimal dosing strategies in this heterogeneous population. These findings support an individualized approach to bevacizumab dosing in radiation necrosis and highlight the need for prospective, tumor-stratified studies.